Literature DB >> 19939227

Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues.

S Darvesh1, G A Reid, E Martin.   

Abstract

Cholinesterase activity associated with neuritic plaques (NPs) and neurofibrillary tangles (NFTs) in Alzheimer's disease (AD) brains exhibit altered histochemical properties, such as requiring lower pH (6.8) for optimal cholinesterase staining compared to the pH (8.0) for best visualization of cholinesterases in neurons. Furthermore, visualization of NPs and NFTs can be prevented by agents like the peptidase inhibitor/metalloantibiotic bacitracin. The anomalous behavior of cholinesterases associated with pathological lesions needs to be elucidated because of the putative links between these enzymes and the disease process in AD. In this study, cholinesterases were extracted from AD and normal brain tissue to determine whether the differences observed in histochemical analyses in the two sources were reflected in kinetic properties measured in solubilized enzymes. Isolated brain enzymes from both these sources exhibited comparable kinetic parameters with respect to pH dependence, substrate affinity and inhibitor sensitivity and were not significantly affected by other agents that blocked cholinesterase histochemical visualization, such as the structurally diverse metal-chelating antibiotics bacitracin, doxycycline, minocycline and rifampicin. Although the cholinesterases from AD brain tissue examined here represented a total pool of these enzymes from AD brain, rather than enzymes specifically from NPs and NFTs, their kinetic behavior being comparable to cholinesterases isolated from normal brain tissues implies that these enzymes do not undergo disease-related modification in their primary structures. This suggests that the atypical histochemical behavior of cholinesterases in NPs and NFTs may result from interaction of cholinesterases with other molecules within these lesions, mediated by transition metal ions known to be present in AD pathology lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19939227     DOI: 10.2174/156720510791383868

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  12 in total

1.  Synthesis and preliminary evaluation of piperidinyl and pyrrolidinyl iodobenzoates as imaging agents for butyrylcholinesterase.

Authors:  Ian R Macdonald; G Andrew Reid; E Eric Joy; Ian R Pottie; Gilbert Matte; Steven Burrell; George Mawko; Earl Martin; Sultan Darvesh
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

2.  A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies.

Authors:  Oksana Gerlits; Kwok-Yiu Ho; Xiaolin Cheng; Donald Blumenthal; Palmer Taylor; Andrey Kovalevsky; Zoran Radić
Journal:  Chem Biol Interact       Date:  2019-06-07       Impact factor: 5.192

3.  Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease.

Authors:  Sultan Darvesh; Meghan K Cash; George Andrew Reid; Earl Martin; Arnold Mitnitski; Changiz Geula
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

4.  Acetylcholinesterase protein level is preserved in the Alzheimer's brain.

Authors:  María-Letizia Campanari; María-Salud García-Ayllón; Lidia Blazquez-Llorca; Wilson K W Luk; Karl Tsim; Javier Sáez-Valero
Journal:  J Mol Neurosci       Date:  2013-12-07       Impact factor: 3.444

5.  Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram.

Authors:  Ryan Walsh; Kenneth Rockwood; Earl Martin; Sultan Darvesh
Journal:  Biochim Biophys Acta       Date:  2011-08-19

Review 6.  New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

Authors:  Nigel H Greig; Marcella Reale; Ada M Tata
Journal:  Recent Pat CNS Drug Discov       Date:  2013-08

7.  Serum cholinesterases are differentially regulated in normal and dystrophin-deficient mutant mice.

Authors:  Andrea R Durrant; Liliya Tamayev; Lili Anglister
Journal:  Front Mol Neurosci       Date:  2012-06-19       Impact factor: 5.639

8.  Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity.

Authors:  Magdalena Markowicz-Piasecka; Joanna Sikora; Łukasz Mateusiak; Elżbieta Mikiciuk-Olasik; Kristiina M Huttunen
Journal:  Oxid Med Cell Longev       Date:  2017-07-09       Impact factor: 6.543

9.  Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.

Authors:  Ian R Macdonald; Selena P Maxwell; George A Reid; Meghan K Cash; Drew R DeBay; Sultan Darvesh
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 10.  Treating Cocaine Addiction, Obesity, and Emotional Disorders by Viral Gene Transfer of Butyrylcholinesterase.

Authors:  Stephen Brimijoin; Yang Gao; Liyi Geng; Vicky P Chen
Journal:  Front Pharmacol       Date:  2018-02-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.